FDA Extends Dermatologic and Ophthalmic Drugs Advisory Committee Mandate

The U.S. Food and Drug Administration has renewed its Dermatologic and Ophthalmic Drugs Advisory Committee for two additional years. This committee provides crucial advice to the Commissioner on the safety and effectiveness of drugs specifically for dermatology and ophthalmology, ensuring continued regulatory oversight in these medical fields.